Skip to main content

Articles

Page 2 of 50

  1. Diabetes mellitus (DM) and cardiovascular diseases often co-exist. Today, percutaneous coronary intervention (PCI) is the preferred revascularization procedure for majority of patients with coronary artery dis...

    Authors: Hong Wang, Xiaoya Xie, Quannan Zu, Ming Lu, Rongfa Chen, Zhiren Yang and Yongqiang Gao
    Citation: Cardiovascular Diabetology 2022 21:220
  2. Authors: Jesus F. Garcia‑Gavilan, Margery A. Connelly, Nancy Babio, Christos S. Mantzoros, Emilio Ros and Jordi Salas‑Salvado
    Citation: Cardiovascular Diabetology 2022 21:219

    The original article was published in Cardiovascular Diabetology 2022 21:189

  3. Few studies have examined the association between hypoglycemic episodes among people with type 2 diabetes (T2DM) at the time of hospitalization for heart failure (HF) and cardiovascular outcomes.

    Authors: Seon-Ah Cha, Jae-Seung Yun, Gee-Hee Kim and Yu-Bae Ahn
    Citation: Cardiovascular Diabetology 2022 21:218
  4. Stress hyperglycemia is strongly associated with poor clinical outcomes in patients with acute coronary syndrome (ACS). Recently, the stress hyperglycemia ratio (SHR) has been proposed to represent relative hy...

    Authors: Wei Xu, Qirui Song, Xiang Wang, Zinan Zhao, Xuyang Meng, Chenxi Xia, Yibo Xie, Chenguang Yang, Ying Guo, Yatong Zhang and Fang Wang
    Citation: Cardiovascular Diabetology 2022 21:217
  5. It is not clear whether pre-existing macrovascular complications (ischemic heart disease, stroke or peripheral artery disease) are associated with health outcomes in people with diabetes mellitus hospitalized ...

    Authors: Gemma Llauradó, Bogdan Vlacho, Matthieu Wargny, Yue Ruan, Josep Franch-Nadal, Pere Domingo, Pierre Gourdy, Pierre-Jean Saulnier, Samy Hadjadj, Sarah H. Wild, Rustam Rea, Bertrand Cariou, Kamlesh Khunti and Dídac Mauricio
    Citation: Cardiovascular Diabetology 2022 21:216
  6. The triglyceride-glucose index (TyG) has been proposed as a surrogate marker of insulin resistance, which is a typical trait of pregnancy. However, very few studies analyzed TyG performance as marker of insuli...

    Authors: Benedetta Salvatori, Tina Linder, Daniel Eppel, Micaela Morettini, Laura Burattini, Christian Göbl and Andrea Tura
    Citation: Cardiovascular Diabetology 2022 21:215
  7. Peripheral arterial disease (PAD) is one of the most disabling cardiovascular complications of type 2 diabetes mellitus and is indeed associated with a high risk of cardiovascular and limb adverse events. High...

    Authors: Maria Margherita Rando, Federico Biscetti, Andrea Leonardo Cecchini, Elisabetta Nardella, Maria Anna Nicolazzi, Flavia Angelini, Roberto Iezzi, Luis H. Eraso, Paul J. Dimuzio, Dario Pitocco, Antonio Gasbarrini, Massimo Massetti and Andrea Flex
    Citation: Cardiovascular Diabetology 2022 21:214
  8. New biomarkers to identify cardiovascular disease (CVD) risk earlier in its course are needed to enable targeted approaches for primordial prevention. We evaluated whether intraindividual changes in blood meta...

    Authors: Daniel Gonzalez Izundegui, Patricia E. Miller, Ravi V. Shah, Clary B. Clish, Maura E. Walker, Gary F. Mitchell, Robert E. Gerszten, Martin G. Larson, Ramachandran S. Vasan and Matthew Nayor
    Citation: Cardiovascular Diabetology 2022 21:213
  9. Data are limited on whether several easily measured indices are independent predictors of type 2 diabetes mellitus (T2DM) in hypertensive patients. This study aimed to assess the association of hypertriglyceri...

    Authors: Hai Deng, Peng Hu, Huoxing Li, Huanning Zhou, Xiuyi Wu, Maohua Yuan, Xueru Duan, Miaochao Lao, Chuchu Wu, Murui Zheng, Xiang Qian Lao, Wenjing Zhao and Xudong Liu
    Citation: Cardiovascular Diabetology 2022 21:212
  10. Patients with type 2 diabetes mellitus (T2DM) are considered as a homogeneous cohort of patients. However, the specific role of diabetic microvascular complications (DMC), in determining the features of corona...

    Authors: Rocco A. Montone, Dario Pitocco, Filippo Luca Gurgoglione, Riccardo Rinaldi, Marco Giuseppe Del Buono, Massimiliano Camilli, Alessandro Rizzi, Linda Tartaglione, Gaetano Emanuele Rizzo, Mauro Di Leo, Andrea Flex, Michele Russo, Giovanna Liuzzo, Giulia Magnani, Riccardo C. Bonadonna, Diego Ardissino…
    Citation: Cardiovascular Diabetology 2022 21:211
  11. Non-obese non-alcoholic fatty liver disease (NAFLD) has been reported to share clinical outcomes with its obese counterpart in the general population. However, conflicting results have been observed regarding ...

    Authors: Ziyin Zhang, Lu Zhang, Wangyan Jiang, Tingting Du and Gang Yuan
    Citation: Cardiovascular Diabetology 2022 21:210
  12. Diagnosing fatty liver and identifying disease status are important for fatty liver related-diseases prevention. The fatty liver index (FLI), which can be easily available in clinical practice, can be very use...

    Authors: In-Ho Seo, Hye Sun Lee and Yong-Jae Lee
    Citation: Cardiovascular Diabetology 2022 21:209
  13. The modification of physical activity (PA) on the metabolic status in relation to atrial fibrillation (AF) in obesity remains unknown. We aimed to investigate the independent and joint associations of metaboli...

    Authors: Ruoting Wang, Ivan Olier, Sandra Ortega-Martorell, Yingxin Liu, Zebing Ye, Gregory YH Lip and Guowei Li
    Citation: Cardiovascular Diabetology 2022 21:208
  14. Compelling evidence suggests that the fibroblast growth factor 23 (FGF23) / α-klotho axis is impaired in subjects with diabetes mellitus. We examined the relationship between parameters related to calcium/phos...

    Authors: Esmeralda Castelblanco, Marta Hernández, Nuria Alonso, Aina Ribes-Betriu, Jordi Real, Minerva Granado-Casas, Joana Rossell, Marina Idalia Rojo-López, Adriana Silvia Dusso, Josep Julve and Didac Mauricio
    Citation: Cardiovascular Diabetology 2022 21:207
  15. Type 1 diabetes is associated with accelerated vascular aging and advanced atherosclerosis resulting in increased rates of cardiovascular disease and premature death. We evaluated associations between Leukocyt...

    Authors: Manuel Sanchez, Caroline Kannengiesser, Sophie Hoang, Louis Potier, Frédéric Fumeron, Nicolas Venteclef, André Scheen, Jean-François Gautier, Samy Hadjadj, Michel Marre, Ronan Roussel, Kamel Mohammedi and Gilberto Velho
    Citation: Cardiovascular Diabetology 2022 21:206
  16. Diabetic cardiomyopathy is characterized by left ventricle dysfunction, cardiomyocyte apoptosis, and interstitial fibrosis and is a serious complication of diabetes mellitus (DM). Autophagy is a mechanism that...

    Authors: Hongchao Wang, Lijie Wang, Fuli Hu, Pengfei Wang, Yanan Xie, Fang Li and Bingyan Guo
    Citation: Cardiovascular Diabetology 2022 21:205
  17. Insulin resistance is an important cause of cardiovascular events and cerebral infarction development. We aimed to investigate the association of the triglyceride glucose (TyG) index with atherosclerotic burde...

    Authors: Mengxing Wang, Lerong Mei, Aoming Jin, Xueli Cai, Jing Jing, Suying Wang, Xia Meng, Shan Li, Tiemin Wei, Yongjun Wang and Yuesong Pan
    Citation: Cardiovascular Diabetology 2022 21:204
  18. Guidelines from 2016 onwards recommend early use of SGLT2i or GLP-1 RA for patients with type 2 diabetes (T2D) and cardiovascular disease (CVD), to reduce CV events and mortality. Many eligible patients are no...

    Authors: Martin Prázný, Lyudmila Suplotova, Janusz Gumprecht, Zdravko Kamenov, Tibor Fülöp, Alexey Medvedchikov, Doron Rosenzweig and Milos Aleksandric
    Citation: Cardiovascular Diabetology 2022 21:203
  19. Severe hypoglycemia is associated with increased cardiovascular death risk, and platelet responses to hypoglycemia (hypo) have been described. However, the impact of deep transient hypo (deep-hypo) versus prol...

    Authors: Abu Saleh Md Moin, Thozhukat Sathyapalan, Stephen L. Atkin and Alexandra E. Butler
    Citation: Cardiovascular Diabetology 2022 21:202
  20. Recent literature reported the biological role of C-peptide, but this role is still controversial and unclear. The primary aim of this study was to investigate associations between C-peptide and cardiovascular...

    Authors: Shuang-Tong Yan, Jing Sun, Zhao-Yan Gu, Xin-Yu Miao, Li-Chao Ma, Ban-Ruo Sun, Xiao-Min Fu, Hong-Zhou Liu, Guang Yang, Fu-Sheng Fang and Hong Li
    Citation: Cardiovascular Diabetology 2022 21:201
  21. Randomised controlled trial showed that dulaglutide can reduce the risk of atherosclerotic cardiovascular disease (ASCVD) in patients with type 2 diabetes mellitus (T2DM), but the underlying mechanisms remain ...

    Authors: Dandan Xie, Yutong Li, Murong Xu, Xiaotong Zhao and Mingwei Chen
    Citation: Cardiovascular Diabetology 2022 21:200
  22. Cardiometabolic multimorbidity (CMM) is becoming increasingly common in patients with hypertension, and it is well established that healthy lifestyle plays a key role in the prevention of hypertension. However...

    Authors: Hejian Xie, Jinchen Li, Xuanmeng Zhu, Jing Li, Jinghua Yin, Tianqi Ma, Yi Luo, Lingfang He, Yongping Bai, Guogang Zhang, Xunjie Cheng and Chuanchang Li
    Citation: Cardiovascular Diabetology 2022 21:199
  23. We performed a study to assess sex-differences in incidence (2016–2020), clinical characteristics, use of therapeutic procedures, and in-hospital outcomes in patients with infective endocarditis (IE) according...

    Authors: Ana Lopez-de-Andres, Rodrigo Jimenez-Garcia, Valentin Hernández-Barrera, Javier de-Miguel-Díez, Jose M. de-Miguel-Yanes, David Martinez-Hernandez, David Carabantes-Alarcon, Jose J. Zamorano-Leon and Concepción Noriega
    Citation: Cardiovascular Diabetology 2022 21:198
  24. Malignant ventricular arrhythmia (VA) is a major contributor to sudden cardiac death (SCD) in patients with pulmonary arterial hypertension (PAH)-induced right heart failure (RHF). Recently, dapagliflozin (DAP...

    Authors: Jinchun Wu, Tao Liu, Shaobo Shi, Zhixing Fan, Roddy Hiram, Feng Xiong, Bo Cui, Xiaoling Su, Rong Chang, Wei Zhang, Min Yan, Yanhong Tang, He Huang, Gang Wu and Congxin Huang
    Citation: Cardiovascular Diabetology 2022 21:197

    The Correction to this article has been published in Cardiovascular Diabetology 2022 21:224

  25. Cell therapy with autologous peripheral blood mononuclear cells (PB-MNCs) may help restore limb perfusion in patients with diabetes mellitus and critical limb-threatening ischemia (CLTI) deemed not eligible fo...

    Authors: Andrea Panunzi, Fabiana Madotto, Elena Sangalli, Federica Riccio, Adriana Barbara Sganzaroli, Paolo Galenda, Amelia Bertulessi, Maria Francesca Barmina, Ornella Ludovico, Orazio Fortunato, Francesco Setacci, Flavio Airoldi, Davide Tavano, Laura Giurato, Marco Meloni, Luigi Uccioli…
    Citation: Cardiovascular Diabetology 2022 21:196
  26. Plasma mannose, an emerging novel biomarker of insulin resistance, is associated with both diabetes mellitus and coronary atherosclerosis, but the relationship between mannose concentrations and myocardial inf...

    Authors: Elena Fortin, Giulia Ferrannini, Beatrice Campi, Linda Mellbin, Anna Norhammar, Per Näsman, Alessandro Saba, Ele Ferrannini and Lars Rydén
    Citation: Cardiovascular Diabetology 2022 21:195
  27. Sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of kidney and heart failure events independent of glycemic effects. We assessed whether initiation of the SGLT2 inhibitor canagliflozin guided...

    Authors: Sok Cin Tye, Niels Jongs, Steven G. Coca, Johan Sundström, Clare Arnott, Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Priya Vart and Hiddo. J. L. Heerspink
    Citation: Cardiovascular Diabetology 2022 21:194
  28. The triglyceride glucose (TyG) index has been suggested as a reliable surrogate marker of insulin resistance which is a substantial risk factor for atherosclerotic cardiovascular disease (ASCVD). Several recen...

    Authors: Shinjeong Song, Su‑Yeon Choi, Hyo Eun Park, Hae‑Won Han, Sung Hak Park, Jidong Sung, Hae Ok Jung, Ji Min Sung and Hyuk‑Jae Chang
    Citation: Cardiovascular Diabetology 2022 21:193
  29. Glucokinase activators (GKAs) are an emerging class of glucose lowering drugs that activate the glucose-sensing enzyme glucokinase (GK). Pending formal cardiovascular outcome trials, we applied two-sample Mend...

    Authors: Ke Wang, Mai Shi, Chuiguo Huang, Baoqi Fan, Andrea O. Y. Luk, Alice P. S. Kong, Ronald C. W. Ma, Juliana C. N. Chan and Elaine Chow
    Citation: Cardiovascular Diabetology 2022 21:192
  30. Duodenal Mucosal Resurfacing (DMR) is an endoscopic ablation technique aimed at improving glycaemia and metabolic health in patients with type 2 diabetes mellitus (T2DM). DMR has an insulin sensitizing effect ...

    Authors: S. Meiring, C. B. E. Busch, A. C. G. van Baar, R. Hemke, F. Holleman, M. Nieuwdorp and J. J. G. H. M. Bergman
    Citation: Cardiovascular Diabetology 2022 21:191
  31. Post-acute sequelae of COVID-19 (PASC), also now known as long COVID, has become a major global health and economic burden. Previously, we provided evidence that there is a significant insoluble fibrin amyloid...

    Authors: Arneaux Kruger, Mare Vlok, Simone Turner, Chantelle Venter, Gert Jacobus Laubscher, Douglas B. Kell and Etheresia Pretorius
    Citation: Cardiovascular Diabetology 2022 21:190
  32. Scientific evidence has accumulated on the beneficial effects of nut consumption on cardiovascular risk and cholesterol reduction, but few studies have examined the effects of nuts on advanced measures of lipo...

    Authors: Jesús F. García-Gavilán, Margery A. Connelly, Nancy Babio, Christos S. Mantzoros, Emilio Ros and Jordi Salas-Salvadó
    Citation: Cardiovascular Diabetology 2022 21:189

    The Correction to this article has been published in Cardiovascular Diabetology 2022 21:219

  33. Multivessel coronary disease (MVCD) is the common type of coronary artery disease in acute coronary syndrome (ACS). Coronary artery calcification (CAC) has been confirmed the strong predictor of major adverse ...

    Authors: Jiayu Wang, Xianwei Huang, Caihua Fu, Qiping Sheng and Ping Liu
    Citation: Cardiovascular Diabetology 2022 21:187
  34. The effect of dapagliflozin (DAPA) on the prognosis of patients with acute myocardial infarction (AMI) is unclear. The present study was conducted to evaluate the association between DAPA administration and ad...

    Authors: Yi Zhu, Jia-li Zhang, Xue-jiao Yan, Ling Sun, Yuan Ji and Fang-fang Wang
    Citation: Cardiovascular Diabetology 2022 21:186
  35. Future risk of cardiovascular disease (CVD) and mortality is associated with cumulative amount TyG index (cumTyG) exposure, while whether time course of TyG accumulation modulates the risk remains unclear. Thi...

    Authors: Xue Tian, Shuohua Chen, Yijun Zhang, Xiaoli Zhang, Qin Xu, Penglian Wang, Shouling Wu, Anxin Wang and Yanxia Luo
    Citation: Cardiovascular Diabetology 2022 21:183
  36. People with intermediate hyperglycemia (IH), including impaired fasting glucose and/or impaired glucose tolerance, are at higher risk of developing type 2 diabetes (T2D) than those with normoglycemia. We aimed...

    Authors: Shishi Xu, Ruth L. Coleman, Qin Wan, Yeqing Gu, Ge Meng, Kun Song, Zumin Shi, Qian Xie, Jaakko Tuomilehto, Rury R. Holman, Kaijun Niu and Nanwei Tong
    Citation: Cardiovascular Diabetology 2022 21:182
  37. The mechanism through which sodium-glucose cotransporter 2 inhibitors (SGLT2i) prevent the incidence of heart failure and/or affect cardiac structure and function remains unclear.

    Authors: Lorenzo Nesti, Nicola Riccardo Pugliese, Paolo Sciuto, Domenico Trico, Angela Dardano, Simona Baldi, Silvia Pinnola, Iacopo Fabiani, Vitantonio Di Bello and Andrea Natali
    Citation: Cardiovascular Diabetology 2022 21:181
  38. Patients with type 2 diabetes (T2DM) present an increased risk of cardiovascular (CV) disease and excess CV-related mortality. Beyond the established role of brain natriuretic peptide (BNP) and cardiac troponi...

    Authors: Jacopo Sabbatinelli, Angelica Giuliani, Anna Rita Bonfigli, Deborah Ramini, Giulia Matacchione, Carla Campolucci, Artan Ceka, Elena Tortato, Maria Rita Rippo, Antonio Domenico Procopio, Marco Moretti and Fabiola Olivieri
    Citation: Cardiovascular Diabetology 2022 21:180
  39. Gestational diabetes mellitus (GDM) is associated with adverse pregnancy outcomes and has maternal health implications reaching beyond the perinatal period. We aimed to investigate the incidence and severity o...

    Authors: Maria Hornstrup Christensen, Katrine Hass Rubin, Tanja Gram Petersen, Ellen Aagaard Nohr, Christina Anne Vinter, Marianne Skovsager Andersen and Dorte Moeller Jensen
    Citation: Cardiovascular Diabetology 2022 21:179
  40. Offspring of mothers with type 1 diabetes have an increased risk for acquiring early onset cardiovascular disease (CVD). Arterial stiffness, measured as pulse wave velocity (PWV), is a non-invasive biomarker f...

    Authors: Cedric A. Korpijaakko, Mia D. Eriksson, Niko S. Wasenius, Miira M. Klemetti, Kari Teramo, Hannu Kautiainen, Johan G. Eriksson and Merja K. Laine
    Citation: Cardiovascular Diabetology 2022 21:178
  41. Obesity is characterized by visceral fat accumulation and various metabolic disturbances that cause metabolic syndrome and obesity-related cardiovascular diseases (ORCVDs). Hence, treatments targeting obesity ...

    Authors: Kosuke Sawami, Atsushi Tanaka and Koichi Node
    Citation: Cardiovascular Diabetology 2022 21:176
  42. To compare the outcomes of diabetic patients hospitalized with non-ST elevation myocardial infarction (NSTEMI) or unstable angina (UA) referred for revascularization by either coronary artery bypass grafting (...

    Authors: Eilon Ram, Enrique Z. Fisman, Alexander Tenenbaum, Zaza Iakobishvili, Yael Peled, Ehud Raanani and Leonid Sternik
    Citation: Cardiovascular Diabetology 2022 21:175
  43. Extracellular vesicles are critical mediators of cell communication. They encapsulate a variety of molecular cargo such as proteins, lipids, and nucleic acids including miRNAs, lncRNAs, circular RNAs, and mRNA...

    Authors: Valeska Ormazabal, Soumyalekshmi Nair, Flavio Carrión, H. David Mcintyre and Carlos Salomon
    Citation: Cardiovascular Diabetology 2022 21:174
  44. Cardiovascular (CV) outcome trials have shown that in patients with type 2 diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces CV mortality and hospital admission rates f...

    Authors: Lucia Leccisotti, Francesca Cinti, Gian Pio Sorice, Domenico D’Amario, Margherita Lorusso, Maria Angela Guzzardi, Teresa Mezza, Shawn Gugliandolo, Camilla Cocchi, Umberto Capece, Luca Indovina, Pietro Manuel Ferraro, Patricia Iozzo, Filippo Crea, Alessandro Giordano and Andrea Giaccari
    Citation: Cardiovascular Diabetology 2022 21:173
  45. Exploratory analysis to determine the effect of semaglutide versus comparators on high-sensitivity C-reactive protein (hsCRP) in subjects with type 2 diabetes.

    Authors: Ofri Mosenzon, Matthew S. Capehorn, Alessandra De Remigis, Søren Rasmussen, Petra Weimers and Julio Rosenstock
    Citation: Cardiovascular Diabetology 2022 21:172
  46. Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE. Tirzepatide is an acylated peptide engineered to activate the GIP and ...

    Authors: Michael A. Nauck and David A. D‘Alessio
    Citation: Cardiovascular Diabetology 2022 21:169

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Annual Journal Metrics